INTERSTITIAL CYSTITIS DRUGS MARKET ANALYSIS

Interstitial Cystitis Drugs Market, By Drug Class (Non-steroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO), Others (Anti-histamines, etc.)), By Type (Non-ulcerative, Ulcerative), By Route of Administration (Oral, Intravesical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global Interstitial Cystitis Drugs Market: Key Developments

On September 15, 2023, West China Hospital, hospital in Chengdu, China, initiated a clinical trial to access the effectiveness and safety of interferon bladder infusions for the treatment of interstitial cystitis.
On May 22, 2023, Vaneltix Pharma, Inc., a pharmaceutical company, in collaboration with Prevail Infoworks, Inc., a system integration and analytics software company, initiated a clinical trial to study the safety and efficacy of VNX001 compared to its individual components (lidocaine and heparin) or placebo in subjects with IC/BPS, which is currently in Phase 2 of the clinical trial and actively recruiting patients.
In July 2022, researchers from Stanford University, U.S., initiated a clinical trial to study low-dose naltrexone for bladder pain syndrome, which is currently in Phase 2 of the clinical trial.
In August 2021, PureTech, a clinical-stage biotherapeutics company, announced that Imbrium Therapeutics, a clinical-stage biopharmaceutical company, had exercised its license option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome. Imbrium Therapeutics had paid PureTech US$ 6.5 million, and PureTech is eligible to receive up to US$ 53 million in additional development milestone payments for this program in addition to royalties on product sales.